Equities

ENDRA Life Sciences Inc

NDRA:NAQ

ENDRA Life Sciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3231
  • Today's Change0.021 / 6.99%
  • Shares traded25.14k
  • 1 Year change-79.75%
  • Beta1.0816
Data delayed at least 15 minutes, as of May 08 2024 20:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.06m
  • Incorporated2007
  • Employees21.00
  • Location
    ENDRA Life Sciences Inc3600 Green Ct Ste 350ANN ARBOR 48105-2440United StatesUSA
  • Phone+1 (734) 335-0468
  • Fax+1 (302) 655-5049
  • Websitehttps://www.endrainc.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cyclacel Pharmaceuticals Inc420.00k-22.76m3.09m12.00--3.68--7.35-26.72-26.720.49240.57320.0228--0.1106---122.40-57.58-212.95-69.81-----5,370.24-18,789.29---170.830.00----22.87-6.34---31.23--
Yield10 Bioscience Inc60.00k-14.46m3.10m29.00------51.72-50.04-50.040.1815-4.950.01--4.002,068.97-241.08-91.26-524.02-108.09-----24,091.67-2,279.74---------86.67-35.94-6.55--1.84--
Applied DNA Sciences Inc9.00m-7.29m3.11m53.00--0.5809--0.3454-10.91-10.9113.566.200.595613.133.99169,733.00-48.39-88.57-59.91-121.9137.6544.35-81.25-113.261.63--0.00---26.4327.92-18.73--33.80--
NovaBay Pharmaceuticals Inc14.73m-16.70m3.12m24.00--0.7122--0.2118-3.82-3.823.500.29511.162.1610.78613,583.30-75.81-61.51-114.10-83.8953.6159.99-65.46-86.470.9998--0.2555--2.243.32-2.66---15.46--
GB Sciences Inc0.00-4.03m3.19m3.00---------0.0105-0.01050.00-0.01190.00----0.00-255.86-49.16---131.40--6.03---995.19---8.63---------2,715.25---60.82--
Optimus Healthcare Services Inc1.27m-7.79m3.20m17.00------2.53-0.1948-0.19480.0317-0.12910.2595--2.1674,453.53-159.79---2,228.37--77.90---615.77--0.1525-15.4121.18--------------
ENDRA Life Sciences Inc0.00-10.06m3.33m21.00--0.5545-----1.93-1.930.000.54470.00----0.00-125.53-132.00-149.91-157.28------------0.005------23.67---19.46--
Kiromic Biopharma Inc0.00-24.99m3.36m31.00---------29.21-29.210.00-3.810.00----0.00-171.18-161.49---213.01-----------15.691.87-------35.90--177.42--
Aditxt Inc645.19k-32.70m3.40m47.00--0.1676--5.27-153.12-153.122.1412.170.02330.89271.3813,727.45-117.12-192.78-251.19-321.59-17.30---5,020.30-7,208.650.2382-4.090.5020---30.90---18.11------
Finch Therapeutics Group Inc107.00k-74.75m3.50m18.00--0.153--32.72-46.59-46.590.066714.250.001--1.49---68.48---74.93-------69,863.55------0.00---87.57--34.80------
Clever Leaves Holdings Inc17.42m-19.80m3.51m296.00--0.1427--0.2015-12.57-11.3811.1114.020.4181.6911.0358,841.21-47.51-23.20-58.14-26.5537.64---113.66-207.521.63-3.700.0479--6.14--47.63------
Altamira Therapeutics Ltd0.00-8.00m3.54m10.00--0.3283-----16.29-8.670.004.810.0034.0532.300.00-103.88-73.80-6,364.67-123.19-87.90------1.38-4.370.00------61.02------
Mustang Bio Inc0.00-51.60m3.55m80.00--22.26-----6.15-6.150.000.01280.00----0.00-93.68-70.02-129.52-79.98-----------15.560.00------33.44---60.75--
Eiger Biopharmaceuticals Inc15.77m-74.96m3.60m25.00------0.2281-50.80-50.8010.69-9.770.19850.00649.19630,920.00-94.31-60.25-186.10-76.5199.91---475.26-823.590.6809-22.031.54--16.98--22.54--10.51--
Data as of May 08 2024. Currency figures normalised to ENDRA Life Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

1.18%Per cent of shares held by top holders
HolderShares% Held
Geode Capital Management LLCas of 31 Dec 202352.18k0.47%
The Vanguard Group, Inc.as of 31 Dec 202339.81k0.36%
NewEdge Advisors LLCas of 31 Dec 202331.26k0.28%
JPMorgan Asset Management (Europe) SARL (Germany)as of 31 Dec 20233.23k0.03%
Tower Research Capital LLCas of 31 Dec 20232.98k0.03%
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023332.000.00%
The Northwestern Mutual Life Insurance Co. (Invt Port)as of 31 Dec 2023329.000.00%
BlackRock Fund Advisorsas of 31 Dec 2023103.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Dec 202358.000.00%
Strategic Advisers LLCas of 31 Dec 20231.000.00%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.